ProMIS Neurosciences Net Worth
ProMIS Neurosciences Net Worth Breakdown | PMN |
ProMIS Neurosciences Net Worth Analysis
ProMIS Neurosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ProMIS Neurosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ProMIS Neurosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ProMIS Neurosciences' net worth analysis. One common approach is to calculate ProMIS Neurosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ProMIS Neurosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ProMIS Neurosciences' net worth. This approach calculates the present value of ProMIS Neurosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ProMIS Neurosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ProMIS Neurosciences' net worth. This involves comparing ProMIS Neurosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ProMIS Neurosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if ProMIS Neurosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ProMIS Neurosciences' net worth research are outlined below:
| ProMIS Neurosciences generated a negative expected return over the last 90 days | |
| ProMIS Neurosciences has some characteristics of a very speculative penny stock | |
| ProMIS Neurosciences has high historical volatility and very poor performance | |
| ProMIS Neurosciences has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (17.51 M) with loss before taxes, overhead, and interest of (16.09 M). | |
| ProMIS Neurosciences has about 8.95 M in cash with (14.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference |
ProMIS Neurosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ProMIS Neurosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProMIS Neurosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know ProMIS Neurosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProMIS Neurosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProMIS Neurosciences backward and forwards among themselves. ProMIS Neurosciences' institutional investor refers to the entity that pools money to purchase ProMIS Neurosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Scotia Capital Inc | 2024-09-30 | 12.1 K | Claret Asset Management Corporation | 2024-09-30 | 11.3 K | Sandy Spring Bank | 2024-09-30 | 3.3 K | Bank Of America Corp | 2024-09-30 | 1.7 K | Royal Bank Of Canada | 2024-09-30 | 746 | Td Waterhouse Canada Inc | 2024-09-30 | 133 | Jpmorgan Chase & Co | 2024-09-30 | 3.0 | Wells Fargo & Co | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 2.7 M | Sphera Funds Management Ltd. | 2024-09-30 | 1.9 M |
Follow ProMIS Neurosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 31.66 M.Market Cap |
|
Project ProMIS Neurosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (3.34) | (3.51) | |
| Return On Assets | (0.97) | (1.02) | |
| Return On Equity | (3.52) | (3.70) |
When accessing ProMIS Neurosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ProMIS Neurosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ProMIS Neurosciences' profitability and make more informed investment decisions.
Evaluate ProMIS Neurosciences' management efficiency
ProMIS Neurosciences has Return on Asset of (4.8073) % which means that on every $100 spent on assets, it lost $4.8073. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (10.9851) %, meaning that it generated no profit with money invested by stockholders. ProMIS Neurosciences' management efficiency ratios could be used to measure how well ProMIS Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to drop to -1.02. In addition to that, Return On Capital Employed is likely to drop to -3.51. At this time, ProMIS Neurosciences' Total Assets are very stable compared to the past year. As of the 11th of December 2024, Other Assets is likely to grow to 1.21, while Non Current Assets Total are likely to drop about 24.5 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.40 | 0.38 | |
| Net Current Asset Value | 583.44 | 518.62 | |
| Tangible Asset Value | 638.17 | 567.26 | |
| Tangible Book Value Per Share | 0.40 | 0.38 | |
| Enterprise Value Over EBITDA | 0.14 | 0.15 | |
| Price Book Value Ratio | 2.84 | 2.70 | |
| Enterprise Value Multiple | 0.14 | 0.15 | |
| Price Fair Value | 2.84 | 2.70 | |
| Enterprise Value | -2.6 M | -2.4 M |
ProMIS Neurosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 3.9 K | Revenue 7.6 K | Revenue Per Share 0.001 | Return On Equity (10.99) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProMIS Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProMIS Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProMIS Neurosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProMIS Neurosciences time-series forecasting models is one of many ProMIS Neurosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProMIS Neurosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ProMIS Neurosciences Earnings per Share Projection vs Actual
ProMIS Neurosciences Corporate Management
| Gail Farfel | Chief Officer | Profile | |
| Daniel MBA | Chief Officer | Profile | |
| Johanne Kaplan | Chief Officer | Profile | |
| Dennis Chen | Head Consultant | Profile | |
| David Wishart | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.